Structure-Based Optimization of a Fragment-like TLR8 Binding Screening Hit to an
In Vivo Efficacious TLR7/8 Antagonist.
ACS Med Chem Lett 2022;
13:658-664. [PMID:
35450354 PMCID:
PMC9014506 DOI:
10.1021/acsmedchemlett.1c00696]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Accepted: 03/08/2022] [Indexed: 11/28/2022] Open
Abstract
Inappropriate activation of TLR7 and TLR8 is linked to several autoimmune diseases, such as lupus erythematosus. Here we report on the efficient structure-based optimization of the inhibition of TLR8, starting from a co-crystal structure of a small screening hit. Further optimization of the physicochemical properties for cellular potency and expansion of the structure-activity relationship for dual potency finally resulted in a highly potent TLR7/8 antagonist with demonstrated in vivo efficacy after oral dosing.
Collapse